Genetic variants in APOE and MAPT have time-dependent effects on cognition, which vary with disease stage: MAPT appears to have its greatest impact on cognitive decline in early PD, whereas APOE may have a more pronounced effect late in the course of the disease (Collins and Williams-Gray, 2016). The gene discussed is APOE; the disease is Parkinson disease.